The FDA's first-ever approval for a chronic hepatitis delta virus treatment is a game-changer. When regulators clear the path for one rare disease therapy, it signals a friendlier environment for others in the pipeline — and smart investors are paying close attention.
Millions of people live with liver conditions that have had little to no treatment options — until now. The companies in this group are at the frontier of changing that, and early movers in rare disease biotech have historically delivered some of the most significant returns.
Professional analysts have hand-picked these stocks specifically for their positioning in next-generation hepatic medicine. From novel drug developers to diagnostic specialists, this basket captures the full value chain of a sector that is rapidly gaining momentum.
The FDA's landmark approval of Gilead Sciences' chronic hepatitis delta virus treatment signals a new era in liver disease medicine. This regulatory milestone reveals that health authorities are ready to clear innovative therapies for complex, previously untreatable conditions — making now a compelling moment to look closely at the companies leading this charge across antiviral solutions, metabolic liver disease, and next-generation diagnostics.
This is a high-growth, thematic basket focused on a specialised corner of healthcare — hepatology and antiviral biotechnology. Many of the companies here are clinical-stage, meaning they are still developing and testing their treatments rather than selling them at scale. That brings exciting upside potential, but also a higher level of risk than more established sectors. This group is best suited to investors who are comfortable with some volatility in exchange for exposure to transformative medical breakthroughs.
Every stock in this group was hand-picked by professional analysts for its direct connection to liver disease innovation — whether that is developing novel drug therapies, manufacturing vaccines, running clinical trials, or providing specialised diagnostic tools. These are not general healthcare picks; they are targeted selections positioned to benefit from shifting clinical standards, increased screening demand, and a favourable regulatory environment for rare disease treatments.
The FDA has granted Gilead Sciences approval for the first-ever treatment targeting chronic hepatitis delta virus. This landmark regulatory decision paves the way for further investments in biotechnology companies developing novel therapeutics for rare and complex liver diseases.
This basket's total market cap is $187.31B and is heavily anchored by a few large-cap constituents, giving it a generally stable, lower-volatility profile.
GILD: $163.06B
MDGL: $11.90B
VIR: $1.67B
+6
Here are a few of the assets in this group. Create an account to unlock the full list.
GILEAD SCIENCES INC
GILD
Current Price
$156.04
Gilead Sciences recently received FDA approval for a groundbreaking chronic hepatitis delta virus treatment, opening new doors for hepatic disease inn...
Gilead Sciences recently received FDA approval for a groundbreaking chronic hepatitis delta virus treatment, opening new doors for hepatic disease innovation.
Join Nemo FREE today and unlock every stock
It only takes 60 seconds.
Use the growth calculator to see how much investing in these assets could return over one year, based on aggregated analyst sentiment provided by Refinitive Ltd.
If you invested across these assets:
In 12 months it might be worth:
+401.08%
On average, analysts expect assets in this group to grow 401.08% over the next year.
15 of 15 assets in this group are rated Buy by professional analysts.
Get the full story on this Basket. Read our detailed article on its risks and potential.
Read Full Insight
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Part of Exinity Group 2015, serving over a million customers globally.
Earn 6% AER on uninvested cash with daily interest payments.
Gilead Sciences has secured FDA approval for a new once-daily HIV combination pill, streamlining therapy for millions of suppressed patients. This regulatory milestone spotlights investment opportunities in pioneering biopharmaceutical companies and drug delivery developers focused on advanced antiviral treatments.
Disney is suing the FCC to block an early license review of its ABC stations, arguing the move is politically motivated retaliation against its news coverage. This unprecedented legal battle highlights the growing regulatory risks for traditional broadcasters and underscores the structural advantages of unregulated digital streaming platforms.
SK Hynix has unveiled a record-breaking 40 trillion won share buyback fueled by soaring demand for its AI memory chips. This historic capital return creates a compelling investment theme centered on high-bandwidth memory producers and the specialized equipment manufacturers that enable their advanced production.
